J Korean Gastric Cancer Assoc.  2003 Mar;3(1):26-32.

Abnormal Fragile Histidine Triad Gene Expression in Gastric Cancer

Affiliations
  • 1Department of Surgery, College of Medicine, Soonchunhyatng University, Chunan, Korea. hychung@knu.ac.kr
  • 2Department of Biochemistry, College of Medicine, Soonchunhyatng University, Chunan, Korea.

Abstract

PURPOSE: Genomic alterations and abnormal expression of the fragile histidine triad (FHIT) gene in gastric cancer were examined to determine whether the FHIT gene is actually a frequent target for alteration during gastric carcinogenesis. MATENRIALS AND METHODS: To correlate DNA and RNA lesions of the FHIT gene with the effect on FHIT protein expression, in 40 gastric cancers, we investigated the FHIT gene for loss of heterozygisity (LOH), aberrant transcripts, and protein expression.
RESULTS
Allelic loss at D3S1300 was detected in 7 of 38 (19%) informative cases. Aberrant transcripts were observed in 20 of 40 (50%) cases. Significant reduction of FHIT protein expression was observed in 22 of 40 (55%) cases. Aberrant FHIT transcription was shown to be associated with loss of FHIT protein expression. However, aberrent FHIT transcripts themselves were not associated with any clinicopathological parameters, such as age, sex, tumor site, or clinical stage. Moreover, there was no association between the presence of LOH at D3S1300 and the expression of aberrant FHIT transcripts.
CONCLUSION
The high frequency of aberrant FHIT transcripts, the significant rate of LOH at D3S1300, and the altered expression of the FHIT protein indicate that alterations of the FHIT gene can play an important role in gastric carcinogenesis.

Keyword

Gastric cancer; FHIT

MeSH Terms

Carcinogenesis
DNA
Gene Expression*
Histidine*
Loss of Heterozygosity
RNA
Stomach Neoplasms*
DNA
Histidine
RNA
Full Text Links
  • JKGCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr